Targeting HSP90 in Non-Small Cell Lung Cancer
Author Information
Author(s): Gallegos Ruiz Mariëlle I., Floor Karijn, Roepman Paul, Rodriguez José A., Meijer Gerrit A., Mooi Wolter J., Jassem Ewa, Niklinski Jacek, Muley Thomas, van Zandwijk Nico, Smit Egbert F., Beebe Kristin, Neckers Len, Ylstra Bauke, Giaccone Giuseppe
Primary Institution: Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands
Hypothesis
Can targeting HSP90 improve survival in non-small cell lung cancer patients?
Conclusion
Targeting HSP90 may have a significant clinical impact on non-small cell lung cancer patients.
Supporting Evidence
- A deletion on chromosome 14q32.2-33 was found in 44% of NSCLC patients.
- Low expression levels of HSP90 were correlated with better overall survival.
- In vitro treatment with an HSP90 inhibitor showed potent antiproliferative activity in NSCLC cell lines.
- Validation sets confirmed the association between low HSP90 expression and improved survival.
Takeaway
Researchers found that a protein called HSP90 is important for lung cancer growth, and that lower levels of this protein can help patients live longer.
Methodology
The study used microarray-based comparative genomic hybridization and gene expression arrays on tumor samples from 32 NSCLC patients.
Limitations
The study had a small sample size and excluded patients with very short survival times.
Participant Demographics
The test set consisted of 32 early stage NSCLC patients, with a median follow-up of 86 months.
Statistical Information
P-Value
0.008
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website